




**CAMPAIGN REPORT AND TRADING
SUMMARY**

APRIL 2016

Campaign Report Summary



LifeSci Capital KOL Series- Acute Sensorineural Hearing Loss (Published 03/04/2016)



Selected buy side firms that viewed the report titled "LifeSci Capital KOL Series- Acute Sensorineural Hearing Loss"

Institutional Investors	Shareholder
Aisling Capital	No
Akahi Capital Management, LLC	No
Alliance Bernstein	No
Alta Partners	No
Alyeska Investment Group	Yes
Aquilo Capital Management, Llc	No
Ardsley Partners, L.P.	No
Armistice Capital Fund LP	No
Aspire Capital Partners, Llc	No
Athyrium Capital Mgmt. LLC	No
AWM Investment Company, Inc.	No
Bailard, Inc.	No
Baker Bros. Advisors, LLC	No
Balyasny Asset Management	No
BlackRock Inc. (BLK)	No
Burrage Capital Partners, LLC	No
Citadel Investment Group, LLC	No
Consonance Capital Management L.P	No
Deerfield Management Company	No
DoubleLine Capital LP	No
Driehaus Capital Management, Inc.	No
Eagle Asset Management	No
EAM Investors LLC	No
Fidelity Management & Research Co.	Yes
First Manhattan Company	No
Foresite Capital	No
Fountain HP	No
Franklin Templeton Investments	No

Selected Buy Side Views Continued



Selected buy side firms that viewed the report titled "LifeSci Capital KOL Series- Acute Sensorineural Hearing Loss"

Institutional Investors	Shareholder	Institutional Investors	Shareholder
Frontier Capital Management	No	Signet Healthcare Partners	No
Gilder Gagnon Howe & Company	No	Sofinnova Ventures	Yes
Granite Investment Partners, LLC	No	Sphera Fund Management	No
Healthcor Partners, LLC	No	T. Rowe Price	No
Highland Capital Management	No	Tang Capital Management, LLC	No
Ingalls & Snyder Asset Management	No	The Boston Company Asset Management, LL	No
Ironwood Investment Management LLC	No	Venrock Associates	No
Jennison Associates LLC	No	Voya Financial	No
Juniper Investment Company Llc	No	Wasatch Advisors Incorporated	Yes
Kingdon Capital Management	No	Wellington Management Company	No
Knoll Capital Management, L.P.	No	Wells Capital Management	No
Lombard Odier Darier Hentsch	No	Woodstock Corporation	No
Longwood Investment Advisors	No	Goldman Sachs Asset Management	No
Millennium Management Llc	No	Opaleye	Yes
Opus Point Partners, LLC	No	Tocqueville Asset Management	Yes
Oracle Investment Management Inc	No		
OrbiMed Advisers Inc.	No		
Palo Alto Investors, LLC	No		
Perceptive Advisers	No		
Perella Weinberg Partners (PWP)	No		
Pura Vida Investments	No		
Putnam Investments Trust	No		
Quogue Capital, LLC	No		
QVT Financial LP	No		
Redmile Group, LLC	No		
Royce & Associates	No		

Selected Industry Insider and Sell Side Views



Selected industry insiders that viewed the report titled "LifeSci Capital KOL Series- Acute Sensorineural Hearing Loss"

Industry Insiders
Brendan Downey, Novartis, brendan.downey@novartis.com
Stefanie Hansen, Pfizer Inc., stefanie.a.hansen@pfizer.com
Jay Kranzler, Pfizer Inc., jay.kranzler@pfizer.com
John Hendrickson, Perrigo Company, john.hendrickson@perrigo.com
Peter Boderke, Merz Pharma, peter.boderke@merz.de
Laura Reilly, Bayer Healthcare Pharmaceutica, laura.reilly@bayer.com
Jerome Zeldis, Celgene Corp, jzeldis@celgene.com
Stacy Coen, Genzyme Corporation, stacy.coen@genzyme.com
John Mchutchison, Gilead Sciences, Inc, john.mchutchison@gilead.com
John Chung, Gilead Sciences, Inc, john.chung@rbccm.com
Jeff Sherman, Horizon Pharma, jsherman@horizonpharma.com
Bob Carey, Horizon Pharma, bcarey@horizonpharma.com
Dominic Caruso, Johnson & Johnson, dcaruso@its.jnj.com
Michael Holston, Merck & Co., Inc., michael.holston@merck.com
Mariah Lopshire, Sanofi, mariah.lopschire@sanofi.com
Nicolas Schlumberger, Sanofi, nicolas.schlumberger@sanofi.com
Yitzhak Peterburg, Teva., yitzhak.peterburg@tevapharm.com
Roni Shiloh, Teva, roni.shiloh@teva.co.il
Ian Smith, Vertex Pharmaceuticals Inc, ian_smith@vrtx.com

Selected sell side firms that viewed the report titled "LifeSci Capital KOL Series- Acute Sensorineural Hearing Loss"

Sell Side Firms	Coverage
Aegis Capital Corp.	No
American Portfolios Financial Svc	No
Robert W. Baird & Co. Inc.	No
Bank of America Corp.	No
Barclays	No
Alliance Bernstein	No
Bishop, Rosen & Co., Inc.	No
Bloom Burton & Co.	No
BTIG, Inc	No
Canaccord Genuity Corp.	No
Chardan Capital Markets, LLC	No
Citigroup, Inc.	No
Ramius Cowen Group, Inc.	No
Credit Suisse	No
Crystal Research Associates LLC	No
Dawson James Securities, Inc.	No
Deutsche Bank AG	No
Edison Investment Research Limited	No
Fbr Capital Markets & Co.	No
ferghanapartners	No
First Analysis Securities Corporation	No
Griffin Securities Inc	No
Guggenheim Partners, LLC	No
Ifs Capital Markets	No
International Strategy and Investment Group	No
Invest Securities	No

Selected Sell Side Views Continued



Selected sell side firms that viewed the report titled "LifeSci Capital KOL Series- Acute Sensorineural Hearing Loss"

Sell Side Firms	Coverage
Janney Montgomery Scott	No
JMP Associates	Yes
Ladenburg Thalmann & Co. Inc.	No
Lake Street Capital Markets Llc	No
Leerink Swann, LLC	Yes
Loeb Partners Corporation	No
Maxim Group, Llc	No
Morningstar	No
Natixis Global Associates	No
Needham & Company, Inc.	Yes
Oppenheimer & Company, LP	No
Piper Jaffray	No
Raymond James	No
RBC	No
Roth Capital Partners, Llc	No
Stifel	No
Summer Street Research Partners	No
SunTrust Banks, Inc.	No
Susquehanna Financial Group, LLLP	No
Washington Analysis	No
Wedbush Securities Inc	No
Wells Fargo & Company	No
William Blair & Company	No

Selected Downloads



Selected downloads for the report titled "LifeSci Capital KOL Series- Acute Sensorineural Hearing Loss"


Name and Firm	Email
Tim Muller, CrossJect	t.muller@crossject.com
Laurent Nguyen, Sensorion Pharma	laurent.nguyen@sensorion-pharma.com
David Munno, Altimune	enright@vaxin.com
Mia Marko, Novartis	mia.marko@novartis.com
Steve Urbach, Chardin	stevenurback@sharton.com
Neal Birnberg, MTI Pharma	birnberg@mtipharm.com
Junichi Hosono, Seikagaku	junichi.hosono@seikagaku.co.jp
Adam Podmore, University of Auckland	a.podmore@auckland.ac.nz
Daniela Fattori, Menarini Group	dfattori@menarini-ricerche.it
Patrick Rivelli, Abrams Capital, LLC	rivelli@ix.netcom.com
Margo Fuld, Aegis Capital Corp.	mfuld@aegiscap.com
Mario Deketelaere, Agfa Healthcare	mario.deketelaere@skynet.be
Greg Flesher, Avanir Pharmaceuticals	gflesher@oticpharma.com
Pascal PAUNOVIC, Belsize Asset Management GmbH	pascal.paunovic@belsize-am.com
Go Saito, Daiichi Sankyo Inc	gsaito@dsi.com
Bill Kridel, ferghanapartners	kridel@ferghanapartners.com
Andrew Stein, First Manhattan Company	astein@firstmanhattan.com
Philip Comby, Hottinger Capital	pcomby@swz.com
Investor Relations, Inovio Biomedical Corporation	investor.relations@inovio.com
Warren Isabelle, Ironwood Investment Management LLC	wisabelle@ironwoodfunds.com
Declan Daly, Isolagen Technologies Inc	ddaly@isolagen.com
Jeanne Bolger, Johnson & Johnson	jbolger@its.jnj.com
Ruchir Sharma, Morgan Stanley Investment Management	kalorama3@yahoo.com
Victor Clavelli, Pfizer Inc.	victor.clavelli@pfizer.com
G'è_nther Metz, Santhera Pharmaceuticals Holding AG	guenther.metz@santhera.com
Gary Jacob, Trovogene	gjacob@trovogene.com
Carl Janson, Zaramant Fonder AB	carlharald.janson@zaramant.com
Michael Nawrath, Zuercher Kantonalbank	michael.nawrath@zkb.ch

Total Cumulative Return vs. BBC

Comparison of Total Cumulative Return (EuCo US Equity vs BBC US EQUITY)



Volume (EuCo US Equity)



The Bioshares Biotechnology Clinical Trials Index (Nasdaq: BBC) comprised solely of pure-play biotechnology companies with an asset in Phase 1 to Phase 3 clinical trials and is therefore representative of the performance of the biotechnology companies with no approved products. Most biotechnology indexes include non-biotech companies and are dominated by large companies with approved products. The BBC should also reflect the volatility of clinical-stage companies, which is typically greater than those with approved products.

Short Interest

EuroCo US Equity

